Unknown

Dataset Information

0

The SARS-CoV-2-neutralizing capacity of kidney transplant recipients 4 weeks after receiving a second dose of the BNT162b2 vaccine.

ABSTRACT:

SUBMITTER: Pedersen RM 

PROVIDER: S-EPMC8450277 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience.
| S-EPMC8397500 | biostudies-literature
Unknown Antibody response after second BNT162b2 dose in allogeneic HSCT recipients.
| S-EPMC8277189 | biostudies-literature
Unknown Early humoral response among lung transplant recipients vaccinated with BNT162b2 vaccine.
| S-EPMC8099313 | biostudies-literature
Unknown Acute myocarditis after receiving first dose of BNT162b2 mRNA vaccine.
| S-EPMC8739668 | biostudies-literature
Unknown Antibody and T-cell response to a third dose of SARS-CoV-2 mRNA BNT162b2 vaccine in kidney transplant recipients.
| S-EPMC8489274 | biostudies-literature
Unknown Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2.
| S-EPMC8309994 | biostudies-literature
Unknown Antibody response to second dose of the BNT162b2 mRNA vaccine in the first 12 weeks in South Korea: A prospective longitudinal study.
| S-EPMC8694796 | biostudies-literature
Unknown A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients.
| S-EPMC8528082 | biostudies-literature
Unknown Faster decay of neutralizing antibodies in never infected than previously infected healthcare workers three months after the second BNT162b2 mRNA COVID-19 vaccine dose.
| S-EPMC8410637 | biostudies-literature
Unknown Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study.
| S-EPMC8577228 | biostudies-literature